Federal Signal Corporation announced a quarterly cash dividend of $0.15 per share, payable on December 1, 2026, to shareholders of record as of November 13, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. Federal Signal, a global manufacturer of infrastructure and safety equipment, continues to support its shareholders through consistent dividend payments.
Federal Signal Corporation's dividend announcement provides context for readers interested in industrials. For readers following Industrials-sector US stocks on Pluang, as of Oct 28, 2026 01:11 WIB, 82 of 135 stocks rose while 52 fell. Among notable movers, XYL (Xylem, Inc.) traded at USD 94.67 with a 12.54% decline and a strong 97% buy order activity, contrasting with EOSE (Eos Energy Enterprises Inc) which gained 11.73% to USD 1.81 but saw more sell orders at 55%. LUNR (Intuitive Machines) rose 10.35% to USD 11.56 amid predominantly sell orders of 91%.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
